Prescribing information

 

Downloadable resources for you and your patients.

Designed to support you and your patients

Risk management materials and healthcare professional materials will provide you with more in-depth information about MAYZENT, and support you in the day-to-day management of patients on MAYZENT.

Materials for patients are designed to help them manage their symptoms, better understand their disease and improve doctor-patient communication.

If you would like to receive printed copies of any of these materials, please contact your local MAYZENT key account manager.

Introduction to MAYZENT
 

INTRODUCTION TO MAYZENT

Patient resource to explain how MAYZENT works and how MAYZENT can help SPMS patients with active disease.

Preview

BEFORE YOU START MAYZENT
 

BEFORE YOU START MAYZENT

Patient resource to provide details around pre-initiation requirement with MAYZENT for SPMS patients with active disease.

Preview

STARTING TREATMENT WITH MAYZENT
 

STARTING TREATMENT WITH MAYZENT

Patient resource to provide details around the treatment initiation process and requirements with MAYZENT for SPMS patients with active disease.

Preview

 
 

CONTINUING TREATMENT WITH MAYZENT
 

CONTINUING TREATMENT WITH MAYZENT

Patient resource to provide details around ongoing monitoring and adherence requirements while on MAYZENT.

Preview

MAYZENT DISCUSSION GUIDES TO SUPPORT HCP DISCUSSIONS WITH PATIENTS
 

MAYZENT DISCUSSION GUIDES TO SUPPORT HCP DISCUSSIONS WITH PATIENTS

Guides to support discussions between HCPs and patients prescribed MAYZENT, introducing the treatment and providing details on pre-initiation, starting and continuing treatment. Included are one discussion guide for HCP use only, providing greater detail on each topic, and one discussion guide for use with patients.

Preview

GP Letter
 

GP LETTER

A letter for GPs of patients who have been prescribed MAYZENT, detailing information relevant to primary care.

Preview

CYP2C9 DRUG-DRUG INTERACTIONS LEAFLET
 

CYP2C9 DRUG-DRUG INTERACTIONS LEAFLET

A leaflet detailing recommendations regarding interactions with the cytochrome P450 pathway in patients who have been prescribed MAYZENT.

Preview

THE EXPAND STUDY ANIMATION
 

THE EXPAND STUDY ANIMATION

A video highlighting key MAYZENT efficacy and safety data for the treatment of SPMS with active disease, as demonstrated in the pivotal phase III study, EXPAND.

View

 

PRESCRIBER'S CHECKLIST
 

PRESCRIBER'S CHECKLIST

A checklist of important points to remember before, during and after treatment with MAYZENT.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

SUMMARY OF PRODUCT CHARACTERISTICS FOR MAYZENT
 

SUMMARY OF PRODUCT CHARACTERISTICS FOR MAYZENT

Summary of product characteristics for MAYZENT.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View  Download

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

MAYZENT PATIENT AND CAREGIVER GUIDE
 

MAYZENT PATIENT AND CAREGIVER GUIDE

A guide detailing important information about MAYZENT for patients and caregivers.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 
 

MAYZENT PREGNANCY CARD
 

MAYZENT PREGNANCY CARD

A card detailing information for female patients of childbearing potential.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

HCP, healthcare professional; SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
     
SIP20-C001j November 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]